DBV Technologies (NASDAQ:DBVT) Price Target Raised to $47.00 at Citizens Jmp

DBV Technologies (NASDAQ:DBVT) had its price objective boosted by equities research analysts at Citizens Jmp from $45.00 to $47.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective points to a potential upside of 126.56% from the company’s previous close.

DBVT has been the topic of a number of other research reports. Guggenheim restated a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research report on Friday. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Sunday, February 8th. HC Wainwright set a $40.00 target price on DBV Technologies in a research note on Thursday, December 18th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.65.

DBV Technologies Stock Up 2.6%

DBV Technologies stock opened at $20.75 on Friday. The firm has a fifty day simple moving average of $21.60 and a two-hundred day simple moving average of $17.15. DBV Technologies has a twelve month low of $5.30 and a twelve month high of $26.18. The company has a market capitalization of $1.15 billion, a PE ratio of -4.01 and a beta of -0.97.

Hedge Funds Weigh In On DBV Technologies

Several large investors have recently modified their holdings of the stock. Artisan Partners Limited Partnership increased its position in shares of DBV Technologies by 6,273.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the last quarter. Siren L.L.C. purchased a new stake in DBV Technologies during the fourth quarter valued at approximately $35,606,000. Vivo Capital LLC increased its holdings in DBV Technologies by 133.4% during the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock valued at $47,189,000 after buying an additional 1,407,120 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in DBV Technologies in the second quarter worth approximately $9,659,000. Finally, MPM Bioimpact LLC bought a new position in DBV Technologies in the second quarter worth approximately $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.